Literature DB >> 23325563

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases.

Anna Demurtas1, Alessandra Stacchini, Sabrina Aliberti, Luigi Chiusa, Roberto Chiarle, Domenico Novero.   

Abstract

A retrospective analysis of 1,792 solid tissues suggestive of lymphoma, submitted over a 12-year period, was carried out and flow cytometry (FC) results were compared with histologic findings. The final histologic diagnosis of cases documented in this report is as follows: 1,270 non-Hodgkin's lymphomas (NHL); 17 composite lymphomas; four NHL plus carcinomas; five post-transplant lymphoproliferative disorders; 105 Hodgkin's lymphomas (HL); eight acute leukemias; 42 tissue cancers; and 341 non-neoplastic diseases. A strong correlation between morphology and FC data was observed among hematological malignancies (1,268/1,304, 97.2%) with the exception of HL. Among B-NHL, FC detection of clonally restricted B-cell allowed the identification of lymphomas that were not histologically clear and the differential diagnosis between follicular lymphoma and reactive hyperplasia. A high correlation level (r = 0.83; P < 0.0001) was obtained in comparing proliferation results obtained by FC and immunohistochemistry. Among T-NHL, FC detection of an aberrant phenotype direct histologic diagnosis in cases having less than 20% of neoplastic cells. In nine cases, FC suggested the need to evaluate a neoplastic population, not morphologically evident. Results show that FC routinely performed on tissue samples suspected of lymphomas is a fundamental adjunct to morphology in the diagnosis of NHL and may enhance the performance of the histologic evaluation so as to achieve the final diagnosis. To the best of our knowledge, this is the first report in the literature of a wide series of tissues also studied by FC.
Copyright © 2013 International Clinical Cytometry Society.

Entities:  

Mesh:

Year:  2013        PMID: 23325563     DOI: 10.1002/cyto.b.21065

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  5 in total

1.  Flow-Cytometry in the Diagnosis of Diffuse Large B-Cell Lymphoma Based on Stomach Tissue Samples: A Case Report.

Authors:  Tung Tuan Nguyen; An Thi Vinh Do; Nga Thi Nguyen; Thanh Quoc Truong; Ai Thuc Ton
Journal:  Cureus       Date:  2022-01-31

2.  Flow immunophenotyping of benign lymph nodes sampled by FNA: Representative with diagnostic pitfalls.

Authors:  Gregory D Scott; Hubert D Lau; Jason H Kurzer; Christina S Kong; Dita A Gratzinger
Journal:  Cancer Cytopathol       Date:  2018-09-07       Impact factor: 5.284

3.  Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India.

Authors:  Prashant R Tembhare; Gaurav Chatterjee; Anumeha Chaturvedi; Niharika Dasgupta; Twinkle Khanka; Shefali Verma; Sitaram G Ghogale; Nilesh Deshpande; Karishma Girase; Manju Sengar; Bhausaheb Bagal; Hasmukh Jain; Dhanalaxmi Shetty; Sweta Rajpal; Nikhil Patkar; Tushar Agrawal; Sridhar Epari; Tanuja Shet; Papagudi G Subramanian; Sumeet Gujral
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

4.  Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.

Authors:  Stefan G C Mestrum; Norbert C J de Wit; Roosmarie J M Drent; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Cytometry B Clin Cytom       Date:  2020-08-28       Impact factor: 3.058

5.  Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

Authors:  A Barreca; C Martinengo; L Annaratone; L Righi; A Chiappella; M Ladetto; A Demurtas; L Chiusa; A Stacchini; N Crosetto; A van Oudenaarden; R Chiarle
Journal:  Blood Cancer J       Date:  2014-10-10       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.